New next-generation microwave thermosphere ablation for small hepatocellular carcinoma
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: In July 2017, the Emprint™ next-generation microwave ablation system using thermosphere technology (Covidien, Boulder, CO, USA) was approved for use in Japan. This system can produce a predictable spherical ablation zone at higher temperatures than radiofrequency ablation (RFA). The aim of the present study was to elucidate whether this new microwave thermosphere ablation (MTA) could safely improve outcome compared to RFA, which is the standard of care for small hepatocellular carcinoma (HCC). Methods: This retrospective study analyzed 513 patients with 630 HCCs (≤3 cm) who were performed by percutaneous RFA (174 patients, 214 HCCs) or MTA (339 patients, 416 HCCs) between January 2016 and March 2020. Results: Median ablation time was significantly shorter for MTA (240 seconds) than for RFA (721 seconds; P<0.001). A significant difference in 3-year local tumor progression rate was evident between the RFA group (22%) and MTA group (8%; P<0.001). Multivariable analysis revealed ablation procedure and tumor diameter as independent factors contributing to local tumor progression (MTA; P<0.001; hazard ratio, 0.565; 95% confidence interval, 0.437–0.731). In patients with primary HCC, a significant difference in overall survival was evident (RFA vs. MTA, 3-year, 77% vs. 95%, P=0.029). Ablation procedure and Child-Pugh score were independent factors contributing to survival. The total complication rate was significantly lower for MTA (8%) than for RFA (14%, P<0.05), particularly for bile duct injury (3% vs. 9%, respectively; P<0.05). Conclusions: Next-generation MTA for small HCC could provide safer, more curative treatment in a shorter ablation time than RFA.
Abstract
Background/Aims: In July 2017, the Emprint™ next-generation microwave ablation system using thermosphere technology (Covidien, Boulder, CO, USA) was approved for use in Japan. This system can produce a predictable spherical ablation zone at higher temperatures than radiofrequency ablation (RFA). The aim of the present study was to elucidate whether this new microwave thermosphere ablation (MTA) could safely improve outcome compared to RFA, which is the standard of care for small hepatocellular carcinoma (HCC). Methods: This retrospective study analyzed 513 patients with 630 HCCs (≤3 cm) who were performed by percutaneous RFA (174 patients, 214 HCCs) or MTA (339 patients, 416 HCCs) between January 2016 and March 2020. Results: Median ablation time was significantly shorter for MTA (240 seconds) than for RFA (721 seconds; P<0.001). A significant difference in 3-year local tumor progression rate was evident between the RFA group (22%) and MTA group (8%; P<0.001). Multivariable analysis revealed ablation procedure and tumor diameter as independent factors contributing to local tumor progression (MTA; P<0.001; hazard ratio, 0.565; 95% confidence interval, 0.437–0.731). In patients with primary HCC, a significant difference in overall survival was evident (RFA vs. MTA, 3-year, 77% vs. 95%, P=0.029). Ablation procedure and Child-Pugh score were independent factors contributing to survival. The total complication rate was significantly lower for MTA (8%) than for RFA (14%, P<0.05), particularly for bile duct injury (3% vs. 9%, respectively; P<0.05). Conclusions: Next-generation MTA for small HCC could provide safer, more curative treatment in a shorter ablation time than RFA.
참고문헌 (20)
- Keun Soo Ahn, "Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation?", Clinical and Molecular Hepatology, 25(4), pp.354~359 (2019), 대한간학회
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Kokudo N, "Clinical practice guidelines for hepatocellular carcinoma : the Japan Society of Hepatology 2017(4th JSH-HCC guidelines)2019 update", Hepatol Res, 49, pp.1109~1113 (2019)
- Crocetti L, "Quality improvement guidelines for radiofrequency ablation of liver tumours", Cardiovasc Intervent Radiol, 33, pp.11~17 (2010)
- Lencioni R, "Loco-regional treatment of hepatocellular carcinoma", Hepatology, 52, pp.762~773 (2010)
- Lubner MG, "Microwave tumor ablation:mechanism of action, clinical results, and devices", J Vasc Interv Radiol, 21(8 Suppl), pp.S192~S203 (2010)
- Alonzo M, "The Emprint™ ablation system with Thermosphere™ technology : one of the newer next-generation microwave ablation technologies", Semin Intervent Radiol, 32, pp.335~338 (2015)
- Vogl TJ, "Evaluation of microwave ablation of liver malignancy with enabled constant spatial energy control to achieve a predictable spherical ablation zone", Int J Hyperthermia, 34, pp.492~500 (2018)
- Lencioni R, "Image-guided ablation of malignant liver tumors : recommendations for clinical validation of novel thermal and non-thermal technologies-a Western perspective", Liver Cancer, 4, pp.208~214 (2015)
- Shimizu R, "Feeding artery ablation before radiofrequency ablation for hepatocellular carcinoma may reduce critical recurrence", JGH Open, 5, pp.478~485 (2021)
- Ahmed M, "Image-guided tumor ablation : standardization of terminology and reporting criteria--a 10-year update", J Vasc Interv Radiol, 25, pp.1691~1705.e4 (2014)
- Facciorusso A, "Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma : a systematic review and meta-analysis", Int J Hyperthermia, 32, pp.339~344 (2016)
- Poulou LS, "Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma", World J Hepatol, 7, pp.1054~1063 (2015)
- Takahashi H, "Local recurrence after microwave thermosphere ablation of malignant liver tumors : results of a surgical series", Surgery, 163, pp.709~713 (2018)
- Suwa K, "Short term treatment results of local ablation with water-cooled microwave antenna for liver cancer : comparison with radiofrequency ablation", Mol Clin Oncol, 12, pp.230~236 (2020)
- Lai ZC, "Do hepatocellular carcinomas located in subcapsular space or in proximity to vessels increase the rate of local tumor progression? A metaanalysis", Life Sci, 207, pp.381~385 (2018)
- An C, "Small single perivascular hepatocellular carcinoma : comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis", Eur Radiol, 31, pp.4764~4773 (2021)
- Jihye Kim, "Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients", Clinical and Molecular Hepatology, 26(4), pp.516~528 (2020), 대한간학회[DOI]
- Sala M, "Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma", Hepatology, 40, pp.1352~1360 (2004)
- Izzo F, "Radiofrequency ablation and microwave ablation in liver tumors : an update", Oncologist, 24, pp.e990~e1005 (2019)